9 results on '"Gambacorta M. A."'
Search Results
2. Functional results after radiochemotherapy and total mesorectal excision for rectal cancer
- Author
-
Coco, C., Valentini, V., Manno, A., Rizzo, G., Gambacorta, M. A., Mattana, C., Verbo, A., and Picciocchi, A.
- Published
- 2007
- Full Text
- View/download PDF
3. Preoperative chemoradiotherapy affects postoperative outcomes and functional results in patients treated with transanal endoscopic microsurgery for rectal neoplasms.
- Author
-
Rizzo, G., Pafundi, D. P., Sionne, F., D'Agostino, L., Pietricola, G., Gambacorta, M. A., Valentini, V., and Coco, C.
- Subjects
RECTUM tumors ,CHEMORADIOTHERAPY ,MICROSURGERY ,RECTAL cancer ,SURGICAL complications ,FACTOR analysis - Abstract
Background: The aim of this study was to quantify the incidence of short-term postoperative complications and functional disorders at 1 year from transanal endoscopic microsurgery (TEM) for rectal neoplasms, to compare patients treated with TEM alone and with TEM after preoperative chemoradiotherapy (CRT) and to analyse factors influencing postoperative morbidity and functional outcomes. Methods: A retrospective study was conducted on all patients treated with TEM for rectal neoplasms at our institution in January 2000–December 2017. Data from a prospectively maintained database were retrospectively analysed. Patients were divided into two groups: adenoma or early rectal cancer (no CRT group) and locally advanced extraperitoneal rectal cancer with major or complete clinical response after preoperative CRT (CRT group). Short-term postoperative mortality and morbidity and the functional results at 1 year were recorded. The two groups were compared, and a statistical analysis of factors influencing postoperative morbidity and functional outcomes was performed. Functional outcome was also evaluated with the low anterior resection syndrome (LARS) score (0–20 no LARS, 21–29 minor LARS and 30–42 major LARS). Results: One hundred and thirteen patients (71 males, 42 females, median age 64 years [range 41–80 years]) were included in the study (46 in the CRT group). The overall postoperative complication rate was 23.0%, lower in the noCRT group (p < 0.001), but only 2.7% were grade ≥ 3. The most frequent complication was suture dehiscence (17.6%), which occurred less frequently in the noCRT group (p < 0.001). At 1 year from TEM, the most frequent symptoms was urgency (11.9%, without significant differences between the CRT group and the noCRT group); the noCRT group experienced a lower rate of soiling than the CRT group (0% vs. 7.7%; p: 0.027). The incidence of LARS was evaluated in 47 patients from May 2012 on and was 21.3% occurring less frequently in the noCRT group (10% vs. 41.2%; p: 0.012). Only 6.4% of the patients evaluated experienced major LARS. In multivariate analysis, preoperative CRT significantly worsened postoperative morbidity and functional outcomes. Conclusions: TEM is a safe procedure associated with only low risk of severe postoperative complications and major LARS. Preoperative CRT seems to increase the rate of postoperative morbidity after TEM and led to worse functional outcomes at 1 year after surgery. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
4. Evidence and research perspectives for surgeons in the European Rectal Cancer Consensus Conference (EURECA-CC2).
- Author
-
Valentini, V., Coco, C., Gambacorta, M. A., Barba, M. C., and Meldolesi, E.
- Abstract
Copyright of Acta Chirurgica Iugoslavica is the property of Association of Yugoslav Surgeons and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
- Published
- 2010
- Full Text
- View/download PDF
5. Could the surgeon trust to radiotherapy help in rectal cancer?
- Author
-
Valentini, V., Gambacorta, M. A., and Barba, M. C.
- Abstract
Copyright of Acta Chirurgica Iugoslavica is the property of Association of Yugoslav Surgeons and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
- Published
- 2008
- Full Text
- View/download PDF
6. Preoperative hyperfractionated chemoradiation for locally recurrent rectal cancer in patients previously irradiated to the pelvis: A multicentric phase II study
- Author
-
Valentini, Vincenzo, Morganti, Alessio G., Gambacorta, M. Antonietta, Mohiuddin, Mohammed, Doglietto, G. Battista, Coco, Claudio, De Paoli, Antonino, Rossi, Carlo, Di Russo, Annamaria, Valvo, Francesca, Bolzicco, Giampaolo, and Dalla Palma, Maurizio
- Subjects
- *
RECTAL cancer , *CANCER treatment , *IRRADIATION , *PELVIC injuries , *RADIATION - Abstract
Purpose: The combination of irradiation and total mesorectal excision for rectal carcinoma has significantly lowered the incidence of local recurrence. However, a new problem is represented by the patient with locally recurrent cancer who has received previous irradiation to the pelvis. In these patients, local recurrence is very often not easily resectable and reirradiation is expected to be associated with a high risk of late toxicity. The aim of this multicenter phase II study is to evaluate the response rate, resectability rate, local control, and treatment-related toxicity of preoperative hyperfractionated chemoradiation for locally recurrent rectal cancer in patients previously irradiated to the pelvis. Methods and Materials: Patients with histologically proven pelvic recurrence of rectal carcinoma, with the absence of extrapelvic disease or bony involvement and previous pelvic irradiation with doses ≤55 Gy; age ≥18 years; performance status (PS) (Karnofsky) ≥60, and who gave institutional review board–approved written informed consent were treated by preoperative chemoradiation. Radiotherapy was delivered to a planning target volume (PTV2) including the gross tumor volume (GTV) plus a 4-cm margin, with a dose of 30 Gy (1.2 Gy twice daily with a minimum 6-h interval). A boost was delivered, with the same fractionation schedule, to a PTV1 including the GTV plus a 2-cm margin (10.8 Gy). During the radiation treatment, concurrent chemotherapy was delivered (5-fluorouracil, protracted intravenous infusion, 225 mg/m2/day, 7 days per week). Four to 6 weeks after the end of chemoradiation, patients were evaluated for tumor resectability, and, when feasible, surgical resection of recurrence was performed between 6–8 weeks from the end of chemoradiation... [Copyright &y& Elsevier]
- Published
- 2006
- Full Text
- View/download PDF
7. Nomograms to predict survival and the risk for developing local or distant recurrence in patients with rectal cancer treated with optional short-term radiotherapy.
- Author
-
van Gijn, W., van Stiphout, R. G. P. M., Van De Velde, C. J. H., Valentini, V., Lammering, G., Gambacorta, M. A., Påhlman, L., Bujko, K., and Lambin, P.
- Subjects
- *
RECTAL cancer treatment , *RECTAL cancer patients , *RECTAL cancer , *RADIOTHERAPY , *KAPLAN-Meier estimator , *CANCER risk factors - Abstract
Background: In many European countries, short-term 5 x 5 Gy radiotherapy has become the standard preoperative treatment of patients with resectable rectal cancer. Individualized risk assessment might allow a better selection of patients who will benefit from postoperative treatment and intensified follow-up. Patients and methods: From patient's data from three European rectal cancer trials (N=2881), we developed multivariate cox nomograms reflecting the risk for local recurrence (LR), distant metastases (DM) and overall survival (OS). Evaluated variables were age, gender, tumour distance from the anal verge, the use of radiotherapy, surgical technique (total mesorectal excision/conventional surgery), surgery type (low anterior resection/abdominoperineal resection), time from randomization to surgery, residual disease (R0 versus R1 + 2), pT-stage, pN-stage and surgical complications. Results: Pathological T- and N-status are of vital importance for an accurate prediction of LR, DM and OS. Short-course radiotherapy reduces the rate of LR. The developed nomograms are capable of predicting events with a validation c-index of 0.79 (LR), 0.76 (DM) and 0.75 (OS). The proposed stratification in risk groups allowed significant distinction between Kaplan-Meier curves for outcome. Conclusion: The developed nomograms can contribute to better individual risk prediction for LR, DM and OS for patients operated on rectal cancer. The practicality of the defined risk groups makes decision support in the consulting room feasible, assisting physicians to select patients for adjuvant therapy or intensified follow-up. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
8. Non-Operative Management Versus Total Mesorectal Excision for Locally Advanced Rectal Cancer with Clinical Complete Response After Neoadjuvant Chemoradiotherapy: a GRADE Approach by the Rectal Cancer Guidelines Writing Group of the Italian Association of Medical Oncology (AIOM)
- Author
-
Domenico Corsi, Michela Cinquini, Federica Grillo, Marco Messina, Chiara Carlomagno, Renato Cannizzaro, Carlo Aschele, Angelo Restivo, Irene De Simone, Brunella Barbaro, Gianluca Masi, Alessandro Pastorino, Gabriele Luppi, Ivan Moschetti, Giulia Capelli, Maria Antonietta Gambacorta, Francesca Valvo, Salvatore Pucciarelli, Gaya Spolverato, Sara Lonardi, Capelli, G., De Simone, I., Spolverato, G., Cinquini, M., Moschetti, I., Lonardi, S., Masi, G., Carlomagno, C., Corsi, D., Luppi, G., Gambacorta, M. A., Valvo, F., Cannizzaro, R., Grillo, F., Barbaro, B., Restivo, A., Messina, M., Pastorino, A., Aschele, C., and Pucciarelli, S.
- Subjects
Oncology ,medicine.medical_specialty ,Metanalysis ,Colorectal cancer ,Writing ,medicine.medical_treatment ,Locally advanced ,Disease ,Medical Oncology ,Neoadjuvant chemotherapy ,Disease-Free Survival ,03 medical and health sciences ,0302 clinical medicine ,Metanalysi ,Internal medicine ,Antineoplastic Combined Chemotherapy Protocols ,medicine ,Humans ,GRADE Approach ,Rectal cancer ,Grading (education) ,Neoplasm Staging ,Settore MED/36 - DIAGNOSTICA PER IMMAGINI E RADIOTERAPIA ,GRADE ,Surgery ,Rectal Neoplasms ,business.industry ,Gastroenterology ,Colostomy ,Chemoradiotherapy ,medicine.disease ,Total mesorectal excision ,Neoadjuvant Therapy ,Clinical trial ,Treatment Outcome ,Neoplasm Recurrence ,Italy ,Local ,030220 oncology & carcinogenesis ,030211 gastroenterology & hepatology ,Neoplasm Recurrence, Local ,business ,Neoadjuvant chemoradiotherapy - Abstract
Background: The standard approach for locally advanced rectal cancer (LARC) is neoadjuvant chemoradiotherapy (nCRT) followed by total mesorectal excision (TME). After nCRT 20% of patients achieve a clinical complete response (pCR) and could be treated with a non-operative management (NOM). Methods: The panel of the Italian Association of Medical Oncology (AIOM) Guidelines on rectal cancer applied the Grading of Recommendations, Assessment, Development and Evaluation (GRADE) approach addressing the following question: Should NOM vs. TME be used for patients with rectal cancer with clinical complete response after nCRT? Five outcomes were identified: disease-free survival (DFS), mortality, local recurrence, colostomy rate, and functional outcomes. Results: Nine studies were included in the analysis. A higher risk of disease recurrence was observed in the NOM group compared to the TME group (RR = 1.69, 95% CI 1.08, 2.64) on the other hand, we observed a slightly positive but not significant effect on mortality of NOM (RR = 0.82, 95% CI 0.46, 1.45). Patients in the NOM group were more likely to experience local recurrence (RR = 5.37, 95% CI 2.56, 11.27) and patients in the TME group were more likely to have a permanent colostomy (RR = 0.15, 95% CI 0.08, 0.29). Only one study evaluated functional outcomes. The overall certainty of evidence was rated as very low. Conclusions: NOM was found to correlate with a higher risk of local recurrence which did not translate in worse OS and a lower colostomy rate. Due to the paucity of evidences, no recommendations are possible. NOM remains an experimental treatment; thus, patients managed with NOM should be enrolled in clinical trials with a dedicated follow-up schedule.
- Published
- 2020
9. Long-Term Outcomes of Local Excision Following Neoadjuvant Chemoradiotherapy for Locally Advanced Rectal Cancer
- Author
-
Antonino De Paoli, Gaya Spolverato, Lucrezia D’Alimonte, Paola Del Bianco, Giovanna Mantello, Laura Albertoni, Giulia Capelli, Mario Guerrieri, Maria Antonietta Gambacorta, Vincenzo Canzonieri, Quoc Riccardo Bao, Vincenzo Valentini, Salvatore Pucciarelli, Claudio Coco, D'Alimonte, L., Bao, Q. R., Spolverato, G., Capelli, G., Del Bianco, P., Albertoni, L., De Paoli, A., Guerrieri, M., Mantello, G., Gambacorta, M. A., Canzonieri, V., Valentini, V., Coco, C., and Pucciarelli, S.
- Subjects
Male ,medicine.medical_specialty ,Colorectal cancer ,Locally advanced ,Rectum ,Disease-Free Survival ,chemoradiotherapy ,Stoma ,Surgical oncology ,80 and over ,medicine ,Rectal Adenocarcinoma ,Humans ,Prospective Studies ,rectal cancer ,Settore MED/36 - DIAGNOSTICA PER IMMAGINI E RADIOTERAPIA ,Aged ,Neoplasm Staging ,Colorectal Cancer ,Aged, 80 and over ,Rectal Neoplasms ,business.industry ,Correction ,Chemoradiotherapy ,Middle Aged ,medicine.disease ,Total mesorectal excision ,Neoadjuvant Therapy ,Surgery ,Neoplasm Recurrence ,Treatment Outcome ,medicine.anatomical_structure ,Local ,Oncology ,Female ,Neoplasm Recurrence, Local ,business - Abstract
Background Local excision might represent an alternative to total mesorectal excision for patients with locally advanced rectal cancer who achieve a major or complete clinical response after neoadjuvant chemoradiotherapy. Methods Between August 2005 and July 2011, 63 patients with mid-low rectal adenocarcinoma who had a major/complete clinical response after neoadjuvant chemoradiotherapy were enrolled in a multicenter prospective phase 2 trial and underwent transanal full thickness local excision. The main endpoint of this study was to evaluate the 5- and 10-year overall, relapse-free, local, and distant relapse-free survival, which were calculated by applying the Kaplan–Meier method. The rate of patients with rectum preserved and without stoma were also calculated. Results Of 63 patients, 38 (60%) were male and 25 (40%) were female, with a median (range) age of 64 (25–82) years. At baseline, the following clinical stages were found: cT2, n = 21 (33.3%); cT3, n = 42 (66.6%), 39 (61.9%) patients were cN+. At a median (range) follow-up of 108 (32–166) months, the estimated cumulative 5- and 10-year overall survival, relapse-free survival, local recurrence-free survival, and distant recurrence-free survival were 87% (95% CI 76–93) and 79% (95% CI 66–87), 89% (95% CI 78–94) and 82% (95% CI 66–91), both 91% (95% CI 81–96), and 90% (95% CI 80–95) and 86% (95% CI 73–93), respectively. Overall, 49 (77.8%) patients had their rectum preserved, and 54 (84.1%) were stoma-free. Conclusion In highly selected patients, the local excision approach after neoadjuvant chemoradiotherapy is associated with excellent long-term outcomes, high rates of rectum preservation and absence of permanent stoma.
- Published
- 2020
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.